Bliss GVS Pharma Limited (BLISSGVS) — Board Meeting

📢 Key Event
Final dividend of Re. 1 per share recommended for FY 2025-26, payable post AGM approval on July 15, 2026.

🔄 What Changed
Declaration of final dividend and mandatory TDS disclosure requirements for shareholders.

🔮 What's Next
Submit bank account and KYC details, along with tax documents, by July 8, 2026, to ensure dividend receipt and applicable TDS rate.

💡 Investor Takeaway
Shareholders must submit required documents by July 8 to avoid higher TDS and ensure dividend eligibility.

Bliss GVS Pharma announced a final dividend of Re. 1 per share for FY 2025-26, payable after shareholder approval at the AGM on July 15, 2026. The company clarified that dividend income is taxable in shareholders' hands, requiring TDS at source under the Income Tax Act, 2025. Resident shareholders may qualify for NIL or lower TDS if they submit valid PAN and meet conditions like receiving less than Rs. 10,000 in dividends or providing Form 121. Non-resident shareholders face a 20% TDS unless they submit documents to claim treaty benefits. Shareholders must update bank and KYC details by July 8, 2026, to ensure timely dividend credit. The TDS certificate will be issued post-payment, and tax credits can be tracked via TRACES.

📄 View Original Announcement (PDF)

📊 Stock Analysis — BLISSGVS ✨ Ask AI About This